Week 9 Discussion – Vaccine-Preventable Diseases
After reviewing the information in Chapter 12 on infectious diseases and reviewing the CDC’s Vaccines and Preventable DiseasesLinks to an external site. web page, focus on and review information on vaccine-preventable diseases, such as shingles.
- Analyze and evaluate the cost effectiveness of vaccinating against the vaccine-preventable disease you chose to review. Suggest at least two recommendations to improve cost effectiveness.
- Provide a rationale for your recommendations.
- Be sure to respond to at least one of your classmates’ posts.
How to solve
SU Vaccine Preventable Discussion
Introduction:
Vaccine-preventable diseases are a significant concern in public health, and it is crucial that medical college students gain a comprehensive understanding of the cost effectiveness of vaccination. In this assignment, we will analyze and evaluate the cost effectiveness of vaccinating against a chosen vaccine-preventable disease, such as shingles. Additionally, we will provide two recommendations to improve the cost effectiveness while providing a sound rationale for our suggestions. This assignment aims to enhance students’ understanding of the economic aspects of vaccine-preventable diseases and encourage critical thinking in improving cost effectiveness.
Answer:
Vaccinating against shingles, a vaccine-preventable disease caused by the varicella-zoster virus, can significantly contribute to reducing the morbidity and healthcare costs associated with this illness. Analyzing the cost effectiveness of vaccinating against shingles requires considering factors such as the cost of the vaccine, disease burden, and potential cost savings from preventing shingles complications.
To evaluate the cost effectiveness, we can employ the concept of incremental cost-effectiveness ratio (ICER). This compares the additional cost of vaccination with the additional health benefits gained, usually measured in quality-adjusted life years (QALYs). By comparing the ICER with a predetermined cost-effectiveness threshold, usually based on a country’s willingness-to-pay, we can determine whether the vaccine is cost effective.
Two recommendations to improve cost effectiveness in vaccinating against shingles are as follows:
1. Promotion of Routine Vaccination: Increasing the uptake of routine vaccination by educating the public, healthcare providers, and policy makers about the benefits and cost savings associated with preventing shingles could enhance cost effectiveness. By emphasizing the long-term cost savings resulting from reduced hospitalizations, complications, and the burden of post-herpetic neuralgia, we can create a stronger case for routine vaccination against shingles. This could be achieved through targeted public health campaigns, educational programs, and ensuring easy access to vaccination services.
2. Negotiating Vaccine Prices: Governments, healthcare systems, and purchasing organizations should actively engage in negotiating vaccine prices to improve cost effectiveness. By leveraging bulk purchasing agreements and negotiating favorable pricing with vaccine manufacturers, the overall cost per dose can be reduced. This would make vaccination programs more affordable, increasing accessibility and improving the cost effectiveness of vaccinating against shingles.
The rationale for these recommendations is rooted in the idea that prevention is often more cost effective than treatment. By investing in routine vaccination, healthcare systems can avoid the significant costs associated with treating shingles and its complications. Moreover, public health interventions that promote routine vaccination can help minimize the burden of shingles on individuals and society.
In conclusion, vaccinating against shingles is a cost-effective measure to reduce the burden of this vaccine-preventable disease. By analyzing the cost effectiveness using tools like ICER and implementing recommendations such as promoting routine vaccination and negotiating vaccine prices, healthcare systems can prioritize prevention and cost efficiency. These measures not only benefit individuals but also contribute to the overall well-being of the population, emphasizing the importance of understanding the economics of vaccine-preventable diseases.
